immunotherapy

Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual MeetingProvectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meeting

Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meeting

Preclinical Research on Full-Thickness Cutaneous Wound Healing KNOXVILLE, TN, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or…

1 year ago
Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology InnovationsEvaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

COPENHAGEN, Denmark, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio…

1 year ago
Umoja Biopharma Announces Appointment of Britton Russell as Chief Financial OfficerUmoja Biopharma Announces Appointment of Britton Russell as Chief Financial Officer

Umoja Biopharma Announces Appointment of Britton Russell as Chief Financial Officer

Britton Russell Britton Russell, Chief Financial Officer, Umoja Biopharma SEATTLE,, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., (Umoja),…

1 year ago
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceG1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today…

1 year ago
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian CancerMemorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE)…

1 year ago
ABVC’s New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion DollarsABVC’s New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars

ABVC’s New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars

FREMONT, CA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing…

1 year ago
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCILIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

Agreement Focuses on Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE…

1 year ago
ASTCT to Present Distinguished Honors at the 2024 Tandem MeetingsASTCT to Present Distinguished Honors at the 2024 Tandem Meetings

ASTCT to Present Distinguished Honors at the 2024 Tandem Meetings

CHICAGO, IL / ACCESSWIRE / February 22, 2024 / American Society for Transplantation and Cellular Therapy® (ASTCT) presents top awards…

1 year ago